Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma
12 hours) shows near complete AR degradation (>98%) in prostate cancer cells
a protein known to be elevated in a variety of tumors
Tyrosine kinase inhibitor SU11274 increased tumorigenicity and enriched for melanoma-initiating cells by bioenergetic modulation
GBR-12935 HCl - CAS# 67469-81-2 Catalog No.:M7140-2 Blockade of XBP1 splicing byGBR 12935 HCl, CAS No. 67469 81 2, is a piperazine derivative which is a potent and selective dopamine reuptake inhibitor. It was originally developed in its 3H radiolabelled form for the purpose of mapping the distribution of dopaminergic neurons in the brain by selective labelling of dopamine transporter proteins. This has led to potential clinical uses in the diagnosis of Parkinson's disease, although selective radioligands such as Ioflupane (I)
US$ 40.00
US$ 26.00
US$ 30.00
US$ 45.00
US$ 30.00
US$ 30.00